RESOURCE USE AND ASSOCIATED COSTS FOR METASTATIC SQUAMOUS NON SMALL CELL LUNG CANCER (SQ NSCLC) PATIENTS: A RETROSPECTIVE CHART REVIEW IN SELECT EUROPEAN COUNTRIES

被引：0
|
作者：
Lorenzo, M. [1 ]
Brown, J. [1 ]
Kurosky, S. [2 ]
Ajmera, M. R. [2 ]
Kaye, J. A. [3 ]
机构：
[1] Eli Lilly & Co Ltd, Windlesham, Surrey, England
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] RTI Hlth Solut, Waltham, MA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2333
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN257
引用
收藏
页码：A755 / A755
页数：1
相关论文
共 50 条
  • [1] HEALTH CARE RESOURCE UTILIZATION AND COSTS OF METASTATIC NON-SMALL CELL LUNG CANCER IN SELECT EUROPEAN COUNTRIES
    Kurosky, S.
    Lorenzo, M.
    Carter, Cuyun G.
    Parikh, R. C.
    Winfree, K.
    Kaye, J. A.
    VALUE IN HEALTH, 2017, 20 (05) : A361 - A361
  • [2] Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
    Sakai, H.
    Nishio, M.
    Hida, T.
    Nakagawa, K.
    Nogami, N.
    Atagi, S.
    Takahashi, T.
    Nokihara, H.
    Saka, H.
    Takenoyama, M.
    Fujita, S.
    Tanaka, H.
    Takeda, K.
    Satouchi, M.
    Isobe, H.
    Maemondo, M.
    Goto, K.
    Hirashima, T.
    Minato, K.
    Tamura, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S111
  • [3] Phase II Studies of Nivolumab in Patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small-Cell Lung Cancer (NSCLC)
    Nakagawa, Kazuhiko u
    Nishio, Makoto
    Hida, Toyoaki
    Sakai, Hiroshi
    Nogami, Naoyuki
    Atagi, Shinji
    Takahashi, Toshiaki
    Nokihara, Hiroshi
    Saka, Hideo
    Takenoyama, Mitsuhiro
    Fujita, Shiro
    Tanaka, Hiroshi
    Takeda, Koji
    Satouchi, Miyako
    Isobe, Hiroshi
    Maemondo, Makoto
    Goto, Koichi
    Hirashima, Tomonori
    Minato, Koichi
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S270 - S271
  • [4] Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients
    Gentili, Nicola
    Balzi, William
    Foca, Flavia
    Danesi, Valentina
    Altini, Mattia
    Delmonte, Angelo
    Bronte, Giuseppe
    Crino, Lucio
    De Luigi, Nicoletta
    Mariotti, Marita
    Verlicchi, Alberto
    Burgio, Marco Angelo
    Roncadori, Andrea
    Burke, Thomas
    Massa, Ilaria
    CANCERS, 2024, 16 (03)
  • [5] Management of Non-Small-Cell Lung Cancer (NSCLC) Stage III Patients in Central European Countries
    Zemanova, Milada
    Zbozinkova, Zuzana
    Pirker, Robert
    Jovanovic, Dragana
    Ceriman, Vesna
    Chaudhary, Subhash
    Richter, Igor
    Bogos, Krisztina
    Hollosi, Virag
    Petruelka, Lubog
    Kufa, Jiri
    Jakubikova, Lenka
    Purkalne, Gunta
    Tiefenbacher, Andreas
    Dieckmann, Karin
    Cernovska, Marketa
    Koubkova, Leona
    Vilasova, Zdefika
    Zemaitis, Marius
    Farkas, Attila
    Spasic, Jelena
    Kozlowski, Miroslaw
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S852 - S853
  • [6] Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
    Jafri, Syed H.
    Shi, Runhua
    Mills, Glenn
    BMC CANCER, 2013, 13
  • [7] Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
    Syed H Jafri
    Runhua Shi
    Glenn Mills
    BMC Cancer, 13
  • [8] Advanced non small cell lung cancer (NSCLC): Observation of chemotherapy in 5 European countries
    Bischoff, H.
    Anderson, H.
    Arellano, J.
    van den Borne, B.
    Langer, F.
    Leschinger, M. I.
    Moneley, C.
    Pimentel, F.
    Riska, H.
    Thatcher, N.
    Visseren-Grul, C.
    Thomas, M.
    ONKOLOGIE, 2008, 31 : 126 - 127
  • [9] Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
    Cramer-van der Welle, Christine
    Peters, Bas J. M.
    Deenen, Maarten J.
    Schramel, Franz M. N. H.
    Van de Garde, Ewoudt M. W.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [10] Costs to healthcare payers associated with clinical trial (CT) participation in metastatic non-small cell lung cancer (NSCLC).
    Merkhofer, Cristina
    Chennupati, Shasank
    Sun, Qin
    Eaton, Keith D.
    Martins, Renato G.
    Ramsey, Scott David
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
12345